The Esophageal Dysphagia market is substantially stimulated by means of the growing incidence of esophageal disorders. Conditions, which include gastroesophageal reflux disease (GERD), achalasia, and esophageal strictures, contribute to the superiority of dysphagia, riding the demand for diagnostic and therapeutic interventions in the market. The market is impacted by demographic developments, especially the growing old global populace. Elderly individuals are more liable to degenerative conditions affecting the esophagus, leading to dysphagia. As the number of older adults increases, the demand for Esophageal Dysphagia answers rises. The occurrence of gastrointestinal disorders, inclusive of inflammatory situations and motility disorders, plays a vast role in shaping the Esophageal Dysphagia market. These problems can cause structural abnormalities and functional impairments in the esophagus, contributing to dysphagia symptoms.
The increasing adoption of endoscopic interventions for the diagnosis and remedy of Esophageal Dysphagia drives the market. Endoscopic strategies, inclusive of dilation, stent placement, and botulinum toxin injections, provide less invasive options to standard surgical tactics, impacting affected person results and market growth. The high occurrence of GERD, a common hazard component for Esophageal Dysphagia, contributes considerably to the market. GERD can result in esophageal strictures and erosions, inflicting swallowing problems. As GERD instances upward thrust, so does the demand for solutions addressing related dysphagia. Lifestyle factors and dietary conduct, which include weight problems and a high-fat eating regimen, are linked to esophageal problems and dysphagia. The market is inspired by using the impact of these lifestyle choices on the prevalence of dysphagia, prompting a need for comprehensive control techniques.
Report Attribute/Metric | Details |
---|---|
Market Size Value In 2023 | USD 1.91 Billion |
Growth Rate | 5.40% (2024-2032) |
Esophageal Dysphagia Market Size was valued at USD 1.91 Billion in 2023. The esophageal dysphagia market industry is projected to grow from USD 2.02 Billion in 2024 to USD 3.09 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 5.40% during the forecast period (2024 - 2032). Aging, cancer, radiation therapy, cardiovascular or respiratory diseases, stroke, and other conditions are the key market drivers enhancing the market growth. The market is expanding due to additional important variables like a shift to a sedentary lifestyle, a side effect of several drugs, and an increase in smoking.
Source Secondary Research, Primary Research, MRFR Database and Analyst Review
Market CAGR for esophageal dysphagia is driven by the rising number of smokers. The growing number of smokers is expected to impact the market's expansion during the projected time. Dysphagia is one of the most severe side effects of long-term cigarette smoking. For instance, the World Health Organisation (WHO), a public health organization headquartered in Switzerland, estimates that by May 2022, tobacco will be a factor in more than 8 million deaths annually. More than 7 million fatalities are due to direct tobacco use, whereas around 1.2 million are from non-smokers exposed to secondhand smoke. While smoking causes the deaths of almost 6 million people annually, the market for esophageal dysphagia is steadily growing because of the increasing incidence of oropharyngeal cancer.
The primary factor influencing the growth rate of the esophageal dysphagia market is the rise in healthcare spending, which aids in constructing its infrastructure. The market for esophageal dysphagia will expand due to increased awareness-raising efforts by public and private organizations. the rising need for dysphagia management in healthcare services and medical institutions, and the increase in disposable money. One of the major elements driving the market is the growing number of smokers who will develop addictions throughout the forecast period. The rising prevalence of dysphagia, particularly among older people, drives the demand for esophageal dysphagia. The market is expanding because of the development of cutting-edge dysphagia management techniques such as video fluoroscopy systems, neuromuscular electrical stimulation devices, and fiberoptic endoscopic evaluation of swallowing (FEES) systems. Thus, driving the esophageal dysphagia market revenue.
The esophageal dysphagia market segmentation, based on diagnosis, includes dynamic swallowing study, x-ray, endoscopy, manometry, imaging scans, MRI scan, and CT scan. The endoscopy segment dominated the market, accounting for 37.5% of market revenue (78.48 Billion). Endoscopy equipment's less intrusive features, and reasonable post- and pre-procedure costs are the main elements projected to boost sector expansion throughout the projection period. The sector for manometry systems is projected to be driven by rising per capita healthcare spending and increased investment in the construction of healthcare infrastructure.
Figure 1 Esophageal Dysphagia Market, by Diagnosis, 2022 & 2032 (USD Billion)
Source Secondary Research, Primary Research, MRFR Database and Analyst Review
The esophageal dysphagia market segmentation, based on treatment, includes esophageal dilation, surgery, stent placement, laparoscopic heller myotomy, medications, and lifestyle changes. Esophageal dilation segment dominated the market in the forecast period. High demand for minimally invasive procedures, rising prevalence of esophageal cancer, malignant & benign illnesses, rising number of surgical operations, and technical advancements in R&D activities are the key factors driving the growth of the esophageal stents segment. Furthermore, surgical treatment saw considerable growth in market share. The need for endoscopic surgery is anticipated to increase due to the increasing prevalence of target diseases like cancer, which will fuel this market's expansion in the future.
The esophageal dysphagia market segmentation, based on product, includes feeding tubes, nasogastric tubes, percutaneous endoscopic gastrostomy, nutritional solutions, thickeners, beverages, purees, drugs, proton pump inhibitors, and others. In 2022, the feeding tubes segment dominated the market. These developments have accelerated the market expansion for feeding tubes. Feeding tubes now have cutting-edge features, such as pressure alarm settings and pre-set cleansing intervals.
March 2021, Applied Medical Technology, Inc. (US) expanded its gastric-jejunal enteral feeding tube family (G-JETS) to include the low-profile micro-G-JET to fulfill the enteral nutrition demands of pediatric patients. The tiny G-JET alternates between a 14F gastric segment and an 8F jejunal segment.
Additionally, in 2022, the proton pump inhibitors segment witnessed the fastest growth rate. The rising incidence of gastroesophageal reflux disease (GERD) and the growing acceptance of novel medicine delivery systems are the two key factors influencing the sector's growth.
The esophageal dysphagia market segmentation, based on end-user, includes hospitals and clinics, ambulatory surgical centers, diagnostic centers, research centers, and others. In 2022, the hospitals segment dominated the market. The key factor driving the hospital segment is the rising prevalence of gastrointestinal and ingestion problems among the aging population. Additionally, it is predicted that the category of ambulatory surgery centers/clinics will experience the highest CAGR throughout the forecast years. Some key factors anticipated to propel the segment's expansion include the increasing desire for minimally invasive procedures to lower total costs and reduce the number of hospital days.
By region, the study provides market insights into North America, Europe, Asia-Pacific and Rest of the World. The North American esophageal dysphagia market area will dominate this market. The rising prevalence of gastrointestinal illnesses, favorable reimbursement practices, an aging population, and the presence of sizable market participants are the primary drivers of the enormous market size in North America. According to an article, GERD affects 18.1% to 27.8% of individuals annually in the United States, making it the most common digestive disorder.
Further, the major countries studied in the market report are US, Canada, France, German, Italy, UK, Spain, Japan, China, Australia, India, South Korea, and Brazil.
Figure 2 ESOPHAGEAL DYSPHAGIA MARKET SHARE BY REGION 2022 (USD Billion)
Source Secondary Research, Primary Research, MRFR Database and Analyst Review
Europe’s esophageal dysphagia market accounts for the second-largest market share. The acceptance of endoscopic operations in this area is driven by the growing senior population and those predisposed to many chronic illnesses. One of the key elements further encouraging market expansion in the region is the increasing government measures to modernize healthcare facilities. Further, the German esophageal dysphagia market held the largest market share, and the UK esophageal dysphagia market was the rapidly growing market in the European region.
The Asia-Pacific Esophageal Dysphagia Market is expected to grow at the fastest CAGR from 2024 to 2032. The area has a sizable unmet need for facilities to treat digestive illnesses, and patient awareness of these facilities is growing, particularly in developing countries like India, China, and Indonesia. As a result, product demand is anticipated to rise throughout the forecasted period. Moreover, China’s esophageal dysphagia market held the largest market share, and the Indian esophageal dysphagia market was the rapidly growing market in the Asia-Pacific region.
Esophageal Dysphagia Key Market Players & Competitive Insights
Leading market players are largely investing in research and development to expand their product lines, which will help the esophageal dysphagia market, grow even more. The launch of new products, larger-scale mergers and acquisitions, contractual agreements, and collaboration with other organizations are significant market developments in which market participants engage to increase their presence. The esophageal dysphagia industry must provide affordable products to expand and thrive in a more competitive and challenging market environment.
One of the major business strategies manufacturers use in the esophageal dysphagia industry to increase market sector and benefit customers is local manufacturing to lower operational costs. In recent years, the esophageal dysphagia industry has stipulated some of the most important medicinal benefits. Major players in the esophageal dysphagia industry, including Nestlé Health Science France, AstraZeneca Plc, Cook Medical Incorporated, Cipla Ltd, Merck Sharp & Dohme Corp, and others, are funding operations for research and development to boost market demand.
Since 1987, Thick-It quick food thickening products have changed how people think about food and dysphagia care. Their mission has been to develop safe products that optimize the daily lives of people who have suffered from dysphagia and have provided treatment to them for over twenty years. They will continue to devote themselves to developing and upgrading products that address the ever-changing needs of people with difficulty swallowing and their carers. In September 2020, Thick-It Brand announced the release of a dysphagia nutrition variety pack. The new packs include Purée Protein, Purée Vegetable, and Ready-to-Drink. The ready-to-drink options come in IDDSI Level 2 - Mildly Thick (nectar) and IDDSI Level 3 - Moderately Thick (honey) consistencies.
Nestlé India Limited is Nestlé's Indian affiliate. Nestlé is a Swiss corporation. The company's main office is in Gurgaon, Haryana. The products that the corporation sells include food, drinks, chocolate, and confections. Nestle, Nescafe, Perrier, Pure Life, and Purina are among its extensive product portfolio brands. In January 2023, Nestlé India introduced ThickenUp Clear, a food and beverage thickening that can aid patients suffering from swallowing difficulties, particularly oropharyngeal dysphagia. It can be given to people with difficulty swallowing due to illnesses including head and neck cancer, stroke, or Parkinson's disease, among others. Dysphagia is a serious but underappreciated health problem that causes dehydration, malnutrition-related illnesses, and a lower quality of life.
Key Companies in the esophageal dysphagia market include
Esophageal Dysphagia Industry Developments
In January 2023, TWi Pharmaceuticals, Inc. ("TWi") announced today the formal introduction of an Authorised Generic of Takeda's Dexilant® (Dexlansoprazole) Delayed-Release Capsules through its wholly owned US subsidiary, TWi Pharmaceuticals USA, Inc. The product is ready for quick dispatch. Dexlansprazole DR Capsules treat heartburn caused by gastroesophageal reflux disease (GERD) and mend erosive esophagitis (esophageal damage caused by stomach acid).
In April 2022, Daewon Pharmaceutical introduced Escorten, one of Korea's earliest proton-pump inhibitor medications. It is a 10mg esomeprazole magnesium trihydrate tablet. The company began developing the medicine in 2019, completed phase 1 clinical trials in the first half of 2020, and demonstrated its efficacy in treating gastritis in large-scale phase 3 clinical trials involving 27 general hospitals.
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)